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Abstract
Background/Aim of the Study: The study aimed to determine the cost impacts of antiretroviral drugs by analysing a long-
term follow-up of direct costs for combined antiretroviral therapy, cART,-regimens in the nationwide long-term
observational multi-centre German HIV ClinSurv Cohort. The second aim was to develop potential cost saving strategies by
modelling different treatment scenarios.
Methods: Antiretroviral regimens (ART) from 10,190 HIV-infected patients from 11 participating ClinSurv study centres have
been investigated since 1996. Biannual data cART,-initiation, cART-changes, surrogate markers, clinical events and the
Centre of Disease Control- (CDC)-stage of HIV disease are reported. Treatment duration was calculated on a daily basis via
the documented dates for the beginning and end of each antiretroviral drug treatment. Prices were calculated for each
individual regimen based on actual office sales prices of the branded pharmaceuticals distributed by the license holder
including German taxes.
Results: During the 13-year follow-up period, 21,387,427 treatment days were covered. Cumulative direct costs for
antiretroviral drugs of J812,877,356 were determined according to an average of J42.08 per day (J7.52 to J 217.70). Since
cART is widely used in Germany, the costs for an entire regimen increased by 13.5%. Regimens are more expensive in the
advanced stages of HIV disease. The potential for cost savings was calculated using non-nucleotide-reverse-transcriptase-
inhibitor, NNRTI, more frequently instead of ritonavir-boosted protease inhibitor, PI/r, in first line therapy. This calculation
revealed cumulative savings of 10.9% to 19.8% of daily treatment costs (50% and 90% substitution of PI/r, respectively).
Substituting certain branded drugs by generic drugs showed potential cost savings of between 1.6% and 31.8%.
Conclusions: Analysis of the data of this nationwide study reflects disease-specific health services research and will give
insights into the cost impacts of antiretroviral therapy, and might allow a more rational allocation of resources within the
German health care system.
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Introduction
The implementation of combined antiretroviral therapy, cART, as
the standard of care since the middle 1990s has substantially reduced
morbidity and mortality in HIV-infected individuals [1,2], leading to
decades of gain in life expectancy for these individuals, comparable to
the normal age-matched population in industrialized countries [3].
Recent standard treatment guidelines recommend cART regimens in
treatment-naive patients consisting of two nucleoside analogues
(nRTI, and, in addition, a non-nucleoside reverse transcriptase
inhibitor (NNRTI), a ritonavir-boosted protease inhibitor (PI/r) or,
more recently, an integrase strand transfer inhibitor (INSTI) [4,5,6].
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The regulation of pricing and the reimbursement of prescription
medicines vary considerably between different countries and result
in notable differences in the market prices of medicinal products
[7]. Prices of antiretroviral drugs in Germany are high – even in
comparison to other industrialized countries – due to national
specifics of the pharmaceutical market. Remarkable differences in
national drug prices were found during an international survey
[8], but the authors did not necessarily see a correlation between
purchase volume and drug prices. Therefore, the authors
hypothesized that the availability of generic drugs next to branded
drugs in the same market would lead to a reduction in prices.
In Germany, the yearly direct costs of HIV disease to the health
care system were estimated as J24,482 per patient in 2001 [9].
But more detailed data of the direct costs for cART in the specific
surroundings of the German health care system are needed to not
only allow an international comparison but also an optimization of
resource allocation. The following specific German conditions
have to be taken into account when analysing the direct costs of
cART:
N Market prices for pharmaceuticals can be calculated by the
manufacturer without negotiation with the authorities or
health care insurers.
N Until recently, health economic aspects were hardly considered
by the German guidelines for antiretroviral treatment.
N Several health care reforms have recently been implemented in
Germany to restrict the increasing expenditure. Equity and
effectiveness should be enhanced by reimbursements that are
calculated on the basis of lump sums for hospital stays
(German disease related groups: G-DRG) and within the
German risk structure compensation for health care insurance.
N In Germany physicians are obligated to the economic efficiency
principle by the German Social Insurance Code, when they
choose treatment alternatives for patients within the statutory
health insurance fund: ‘‘Services must be sufficient, appropri-
ate, and cost-effective; they must not go beyond the
indispensable minimum’’ [10].
The knowledge on the impact of the use of antiretroviral
treatment on direct costs within the German health care system is
scarce [11,12]. A long-term follow-up of direct costs for cART
regimens in the nationwide German ClinSurv multi-centre cohort
will allow elucidation of the impact of more recently licensed
antiretroviral drugs and the evolution of treatment guidelines for
this cost-setting, economic and main part of the care of HIV/
AIDS. The main aim of this study was to determine the trend
dynamics of direct costs associated with the implementation of
cART in clinical practice that reflect the prescribing patterns of
particular antiretroviral drug regimens. The second aim was to
estimate the potential impact of the introduction of generic
antiretrovirals on the direct treatment costs of HIV in the German
pharmaceutical market.
Methods
By law (National protection against Infection act, IFSG, 2001)
the Federal Commissioner for Data Protection and Freedom of
Information recommended the clinical surveillance of HIV-
infection in Germany. The Clinical Surveillance of HIV Disease,
ClinSurv study, was approved by the Federal Commissioner for
Data Protection and Freedom of Information. No personal data
and no biomaterials are collected. The Federal Commissioner for
Data Protection and Freedom of Information waived the need for
written consent, because data are reported anonymously to the
German Public Health Institute, the Robert Koch-Institute. The
ClinSurv study is an ongoing, prospective, long-term observational
cohort study. The study design is described in detail elsewhere
[12]. Up to the present study, a total of 14,377 HIV-infected
patients monitored at 11 clinical centres in different, predomi-
nantly urban areas in Germany have been enrolled in the study
and consecutively monitored since January 1st 1999.
Due to the fact that the cohort enrolment was initiated in the
pre-cART era, patients on single-drug cART or double-combi-
nation cART, as well as patients on cART, were included in the
cohort. A biannual data collection was performed using local
electronic databases that capture information on antiretroviral
therapy, treatment initiation and changes in treatment since the
first visit to the reporting centres. Immunologic, virologic and
demographic data, AIDS-defining diagnoses and information on
cART are reported. All time-related variables were collected and
referenced according to their days of occurrence. The data were
validated and monitored manually as well as electronically at the
coordinating centre. The source data were verified and double
reporting was excluded.
The history of antiretroviral therapy administration was
documented individually by beginning and end dates and the
administered dosages were calculated on a daily basis for every
single antiretroviral drug. The active substances in each particular
pharmaceutical ingredient are categorized by their International
Non-proprietary Names (INN). All INN were categorized within
their appropriate substance classes, which are defined by their
mode of action (Table 1). In addition, the ingredients of co-
formulated drugs were assigned to the single antiretroviral agents
included.
Treatment entities are defined as substance regimen (SR) by lists
of pharmaceutical ingredients or as class regimen (CR) by the list
of their dedicated substance classes for all individual antiretrovirals
taken at the same time. The amounts of all single drugs and the
numbers of antiretrovirals representative for each single substance
class were calculated and defined as the daily swallowed pill
burden. The regimens were defined as PI-boosted if ritonavir was
added to another PI in a daily dose of less than or equal to 400 mg
per day, whereas ritonavir was regarded as an antiretroviral active
drug when given in a higher dosage. In order to assign an
individually appropriate treatment line, the cART history was
retrospectively documented in all patients who started cART
before entering the study. Any qualitative change of treatment
regimen defined a subsequent regimen and via this an incremen-
tally increasing treatment line. If it was known that a patient was
treatment naive, a regimen was defined as the first line regimen.
Treatment naive patients were not included in the cost analysis
unless at the point of initiation. Treatment interruption was
defined as any period without the intake of cART by a previously
treated patient.
Allocation of direct treatment costs
Allocation of direct costs for cART was calculated by daily
standard doses for all elements of an entire regimen (treatment
days) on the basis of historical and actual office sales prices of the
original pharmaceuticals distributed by the license holder; the
prices include German taxes as given in the German pharmaceu-
tical online database (Lauer Taxe; www.lauer-fischer.de). No
direct costs were assigned for particular antiretroviral substances
during periods of early access programmes before licensing of the
drug in Germany. Treatment costs were calculated exclusively for
the days under treatment with at least one antiretroviral drug,
including hydroxyurea, which was assumed to have antiretroviral
effects in the late 1990s. The potential impact of discarded drugs
Direct Costs of Antiretroviral Treatment
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when regimens were changed and when non-adherence (e.g.
forgotten doses) was reported were not included in the cost
analysis. The mean costs over time were adjusted for the annual
German consumer price indices (German Federal Statistical Office
2010, www.destatis.de; 1996= 100%). The German national
annual increments of the consumer price index in percentages
were: 1996: 1.4%, 1997: 1.9%; 1998: 1.0%; 1999: 0.6%; 2000:
1.4%; 2001: 1.9%; 2002: 1.5%; 2003: 1.0%; 2004: 1.7%; 2005:
1.5%; 2006: 1.6%; 2007: 2.3%; 2008: 2.6%.
Calculation of cost saving strategies with NNRTI or
potential generics/sensitivity analysis
Estimates of the cost impact of the use of a preferred NNRTI
instead of PI, and rates of 50% and 90% substitution of PI(/r) by
NNRTI in first line therapy were calculated. Assuming that in the
near future generic zidovudine, lamivudine, nevirapine and
efavirenz will be available in Germany, the potential cost impact
of using these generic drugs was modelled. Scenarios with a price
reduction between 20% and 90%, as compared to the recent
prices for branded drugs, and prescription rates of 20% up to 90%
for applicable generic drugs were calculated. For the purposes of
this analysis it was also assumed that branded emtricitabine could
be substituted by generic lamivudine in certain cases.
Statistics
Quarterly datasets were determined for the observation period.
Statistical analysis was performed using PASW 18 statistical
software. Mean values and their standard deviations were
calculated. Differences between the means were compared by
ANOVA tests. The p-values of,0.05 were considered as denoting
statistical significance, and all tests of significance were two-sided.
Results
Study population of the ClinSurv Cohort
In total, 10,190 HIV-positive patients observed in the German
ClinSurv Cohort were enrolled in the study during the period of
January 1st 1996 to December 31st 2008. Nearly 80% of these
patients were male, 75% were German born, and over 60% were
symptomatic according to CDC-B and CDC-C classification
(Table 2). The women were younger (median of 32 years old) than
the men (median 38 years old). The period between the first
diagnosis of HIV in women and their first clinical site visit in one
of the participating study centres was shorter than for the men.
The women were in earlier stages of HIV disease and had histories
with less advanced treatment lines than the men. Any PI-based
regimen was prescribed less frequently (42% of treatment days) for
the women than for the men (50%). Treatment lines, stages of
HIV disease, time of first diagnosis, and age also differed between
groups, with distinct transmission risks and different ethnic groups.
During the 13-year follow-up period 21,387,427 individual
treatment days were covered (Figure 1). A cumulative direct cost of
J812,877,356 for antiretroviral drugs was calculated. The average
cost per day was J42.08 (J7.52–217.70). Out of 21.39 million
documented treatment days, 1.99 million were assigned to
Table 1. Licensed antiretroviral drugs and their assigned substance classes.
Antiretroviral substance (INN) Abbreviation Class (defined by mode of action) German launch date (month/year)
Abacavir ABC nRTI 07/1999
Didanosine ddI nRTI 9/2000
Emtricitabine FTC nRTI 10/2003
Lamivudine 3TC nRTI 08/1996
Stavudine d4T nRTI 05/1996
Tenofovir TDF nRTI 11/2001
Zalcitabine ddC nRTI Before 1996
Zidovudine AZT nRTI Before 1996
Efavirenz EFV NNRTI 5/1999
Nevirapine NVP NNRTI 2/1998
Amprenavir APV PI 10/2000
Atazanavir ATV PI 03/2004
Darunavir DRV PI 02/2007
Fosamprenavir FPV PI 07/2004
Indinavir IDV PI 10/1996
Lopinavir LPV PI 03/2001
Nelfinavir NLF PI 01/1998
Ritonavir RTV PI 08/1996
Saquinavir SQV PI 08/1998
Tipranavir TPV PI 10/2005
Enfuvirtide T20 FI 5/2003
Maraviroc MVC CCRI 09/2007
Raltegravir RAL INSTI 12/2007
Hydroxyurea HU RRI Before 1996
Abbreviations see glossary.
doi:10.1371/journal.pone.0023946.t001
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treatment interruptions. The average direct costs for treatment
days were decreased by 9.7% (to J38.00) when these interruptions
were included in the analysis. Treatment interruptions appeared
less frequently in 1997 (5.3%), were predominantly reported in
2003–2004 (12.1% per year), and decreased again in 2008 (6.3%).
Composition of treatment regimens in the ClinSurv
Cohort
The mean number of drugs increased continuously during the
observation period (1996: 2.05 vs. 2008: 3.62). Each regimen was
comprised of 3.4 substances (mean +/20.79), including ritonavir.
Ritonavir appeared in 33% of all regimens prescribed. The
regimens with boosted PI/r contained significantly more antiret-
roviral components (4.2+/20.65) and ARV classes (2.07+/20.39)
than non-boosted regimens (substances: 3.05+/20.54; ARV
classes: 1.87+/20.43, p,0.0001; Figure 2).
A predominance (51.0%) of PI/r-based treatment regimens was
reported in the entire cohort (n = 249,340 treatment quarters).
When analysing patients exclusively on their first line treatments
(n = 62,966 treatment quarters), PI based regimens (52.3%)
predominate as well NNRTI-based regimens, but NNRTI
outweigh the P based regimens in second- (51.8%; n= 39,780
treatment quarters) and third-line regimens (50.6%; n= 33,333
treatment quarters). NNRTIs were available later than PI, and
therefore the use of NNRTI increased over time in early treatment
lines. In 1998: 12.7% in first, 14.6% in second, and 12.1% in third
line treatment as compared to 51.2%, 58.9% and 54.2% in 2008.
Until 2001, virtually all regimens consistently contained one or
more nRTIs. In contrast, in later treatment, the lines that switched
from NNRTI to PI/r prevailed.
The proportion of more recently licensed drug classes (fusion
inhibitor FI, integrase strand transfer inhibitor INSTI, chemokine
co-receptor inhibitor: CCRI) was cumulatively less than 5%
among all of the ARV regimens reported in 2008, with a tendency
to increase. Overall, 2.2 different single antiretroviral substance
regimens were prescribed in the cohort and 197 different drug
class regimens (Table 3) were composed. However, the top ten
class regimens covered more than 90% of all prescribed regimens.
The top ten drug compositions represented more than a third of all
drug regimens. Zidovudine/lamivudine-containing regimens were
the dominant regimens during the observation period. They
decreased from 80% in 1996 to 25% in 2008, whereas tenofovir,
comprising a backbone, increased from 0% to 62% (Figure 3).
Up to 48 treatment lines were documented within the
observation period. The means and maximums of treatment lines
increased during the 13 year follow-up period. The proportion of
patients who received a first line regimen was highest at the start of
the observation period in 1996 (39.6%) and lowest in 2008 (21.6%;
Table 4).
Drug costs – status quo in the German ClinSurv Cohort
Between 1996 and 1999 the mean daily drug costs for an entire
regimen increased substantially (+72%: J21.89+/29.57 to
J37.70+/29.21) by the introduction of triple c-ART. Since
1999 the increase in daily drug costs was more moderate until
2008 (33%: J 50.05+/216.47). As a consequence of a 16% price
cut enacted by law, a sharp decline of 15.4% was observed
between 2003 (J45.82) and 2004 (J38.75). After adjusting costs
for the annual German consumer price indices (German Federal
Statistical Office 2010, 1996= 100%), the real increase in daily
drug prices for the prescribed cART regimen in the cohort was
13.5% (1999: mean: J36.39/d and 2008: mean: J41.32/d,
Figure 4).
Substantial differences in average drug prices existed between
different antiretroviral classes. Within the same drug classes,
differences between substances were comparatively small. Patients
in advanced treatment lines received more complex and more
expensive regimens. Expenditures for PI, INSTI, CCRI and
Fusion Inhibitors (FI) increased substantially in advanced treat-
ment lines, but remained constant for nRTI, and decreased for
NNRTI (Figure 5).
In symptomatic HIV-disease stages the mean daily drug costs
for cART were higher (CDC-B: J42.33+/214.34, n= 53,239
regimen quarters; CDC-C: J44.45+/215.00, n= 86,615 regimen
quarters) compared to patients with asymptomatic or unknown
stages of HIV (J40.09+/211.84, n = 109,486 regimen quarters;
p,0.0001). Differences were less pronounced than those between
treatment regimen lines, reflecting the fact that complex treatment
histories were also seen in less advanced stages of the disease.
The direct costs of cART were lower for females (J40.42+/
212.65) than males (J42.46+/213.88, p,0.0001). The amount
of daily swallowed pills (pill burden) decreased via the incremental
use of fixed drug combinations from 11.02 bits/day (+/25.11) in
Table 2. Patients’ characteristics at the time when their first
cART regimen was documented within the ClinSurv cohort.
n (%)
Total number of cases 10,190
Gender
Female 2062 (20.2%)
Male 8128 (79.8%)
Risk
Men who have sex with men (MSM) 5112 (50.2%)
Intravenous drug use (IDU) 973 (9.5%)
Transfusion/Haemophilia 186 (1.8%)
Heterosexual 1421 (13.9)
Origin from high prevalence region 1300 (12.8%)
Vertical transmission 20 (0.2%)
Unknown/other 1178 (11.6%)
Origin
Germany 7653 (75.1%)
Western Europe 353 (3.5%)
Central- & Eastern Europe 452 (4.4%)
Sub-Saharan Africa 1025 (10.1%)
Asia/Northern Africa 326 (3.2%)
Americas/Caribbean 179 (1.8%)
Unknown/other 202 (2.0%)
CDC-Stage
CDC-A/unknown 4038 (39.6%)
CDC-B 2105 (20.7%)
CDC-C 4047 (39.7%)
Age (years)
Mean (+/2 SD) 38 (+/210.7%)
Median (range: min-max) 36 (2–81%)
Year of first HIV diagnosis
Range (min - max) 1984–2008
Observation period
Range 1.1.1996–31.12.2008
doi:10.1371/journal.pone.0023946.t002
Direct Costs of Antiretroviral Treatment
PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e23946
1998 to 4.53 bits/day (+/22.63) in 2008. In parallel, the
proportion of regimens with three or fewer pills per day increased
from 5.6% to 41.1% in 2008, hence the price per bit increased
substantially from J3.38 to J14.22 per day during that time
(Figure 6).
Potential cost savings by modelling the different
treatment strategies: Cost impact of NNRTI vs. PI in first
line cART
Overall, 4.9 million out of 19.4 million treatment days in this
cohort (25.3%) referred to patients receiving first line therapy. The
proportions of NNRTI- and PI-comprising first line regimens were
comparable (NNRT: 41.4%; PI/r 45.7%). In contrast, the mean
daily costs of the PI/r regimen were higher than the costs of
NNRTI-comprising regimens (PI/r: J22.07; NNRTI: J14.32).
Hypothetically, assuming that at least 50% and as much as 90% of
a PI/r-comprising first line regimen could be substituted by less
expensive NNRTIs, this change would result in cumulative savings
of 10.9% to 19.8% respectively, of the daily treatment costs.
Potential cost impact of generic antiretrovirals
Of all of the direct costs of antiretroviral drugs, 44.4% are
related to the use of zidovudine, lamivudine, emtricitabine,
nevirapine and efavirenz, which were exclusively available as
branded drugs within the observation period. These drugs might
be candidates for substitution by generic drugs or equivalents in
the near future in Germany. The relative cost impact of these
potentially replaceable branded drugs decreased from 44.1% in
2005 to 34.9% in 2008 for all of the mean direct costs of
antiretrovirals (Table 5).
Figure 1. Cumulative use (in days) of antiretroviral classes by year. (* The decrease of treatment days in 2008 is explained by a reporting
delay for some of the most recent cases within the database at the end of the observation period).
doi:10.1371/journal.pone.0023946.g001
Figure 2. Distribution of the amount of different antiretrovirals per regimen in % of all treatment days. Observation period 1996–2008.
doi:10.1371/journal.pone.0023946.g002
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Using different hypothetical price cuts related to the use of
generic drugs (from 20% up to 90% as compared to recent prices
of the branded drugs) and different rates of substitution of the
branded ARVs by generics (20% to 90%), the potential impact for
cost savings was calculated as ranging from 1.6% up to 31.8% of
the direct costs of all prescribed antiretrovirals (modelling utilized
the most recent data from 2008, Table 6).
Discussion
The German health care system has set up some unique
regulations regarding pricing policies for over-the-counter drugs
(or the OTC market) and for drugs only available on prescription
[13]. Besides this, manufacturers have the right to fix branded
drug prices at desired levels largely without negotiation with the
authorities or insurance companies. Therefore, German drug
prices have an important impact on the EU-wide market. In
addition, branded drugs are sold in German pharmacies
nationwide on the basis of the price, which is fixed by the
manufacturer. Both features are reasons for the comparably higher
pricing of branded drugs in Germany [8]. However, statutory
discounts and reference pricing lists have recently been modified
by legal regulations [14]. A statutorily ordered price cut of 16% in
2004 led to a sustainable reduction of the increase in antiretroviral
drug prices for several years in the cohort studied (Figure 4).
Use of substance classes and the reflectance of treatment
guidelines
Cost analyses take the cost-bearer’s view and therefore the costs
of antiretrovirals given in clinical trials or expanded access
programmes are disregarded. Thus, the monetary assessment of
cART in this study should almost exclusively reflect the
antiretroviral regimens in clinical day life, which should be geared
towards current national treatment guidelines [4]. The primary
goals of these guidelines are the initiation of first line antiretroviral
therapy and the implementation of principles for proceeding in
cases of treatment failure.
Within a clinical setting there might be a need to change an
antiretroviral regimen due to several reasons, which can result in a
Figure 3. Market share of selected antiretrovirals of the nRTI-class (% of all treatment days per year).
doi:10.1371/journal.pone.0023946.g003
Table 3. Top ten antiretroviral substance regimens (n = 2226) and class regimens (n = 197).
Substance regimen
Number of regimen
quarters
Cumulative
frequencies in % Class regimen
Number of regimen
quarters
Cumulative
frequencies in %
1 AZT/3TC/NVP 19,558 7.8 NNRTI + 2 nRTI 83,874 33.6
2 AZT/3TC/EFV 15,745 14.2 PI/r + 2 nRTI 56,417 56.3
3 TDF/FTC/EFV 10,627 18.4 PI + 2 nRTI 31,940 69.1
4 AZT/3TC/LPV/r 9665 22.3 3 nRTI 12,955 74.3
5 AZT/3TC/ABC 9006 25.9 2 nRTI 11,985 79,1
6 TDF/FTC/LPV/r 6798 28.6 NNRTI + 3 nRTI 9685 83.0
7 AZT/3TC/IDV 6090 31.1 PI/r + 3 nRTI 8307 86.3
8 AZT/3TC 5605 33.3 2 PI + 2 nRTI 5502 88.5
9 TDF/FTC/ATV/r 5094 35.4 PI/r + NNRTI + 2 nRTI 3395 89.9
10 TDF/FTC/NVP 5088 37.4 PI + NNRTI + 2 nRTI 2842 91.0
doi:10.1371/journal.pone.0023946.t003
Direct Costs of Antiretroviral Treatment
PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e23946
rather short median duration of first line regimens of a couple of
months [15]. This might explain the considerable diversity in
antiretroviral treatment within the ClinSurv cohort, resulting in
more than 2000 different antiretroviral substance regimens.
However, 37.4% of these regimens were covered by the top ten
SRs and 80.5% by the top one hundred, respectively. Analyses of
the patterns of the prescribed cART regimens demonstrated an
almost complete compliance with the actual treatment guidelines
at any time.
Variations and clusters of certain regimens between participat-
ing centres were obviously determined by on-going studies or by
the pre-selection of patients with particular co-morbidities or more
advanced stages of HIV at some of the ClinSurv centres. For
example, boosted double PI-regimens were not recommended by
German treatment guidelines but they still accounted for a 1.0% of
all documented regimens within the cohort. These patients
predominantly presented at particular study centres.
Treatment recommendations from the treatment guidelines
reflected rather data regarding efficacy and tolerability from
clinical trials than health and economic considerations [16]. Yet,
in Germany, physicians are obliged to prescribe the economically
most advantageous alternative within the publicly funded health
care system. However, this stipulation is restricted to equipollent
treatment options, which are hardly defined in clinical practice.
On the other hand, until recently, treatment guidelines did not
discuss the cost impacts of the given recommendations. The
NNRTI- and PI/r-based drug regimens are equally recommended
for first line treatment in recent guidelines [4,5]. The mean daily
costs of PI/r were found to be 53.8% greater than for NNRTI
within the treatment days in this cohort, which referred to patients
who received first line therapy. Among the initial regimens, the
distribution of NNRTI and PI/r-based regimens was almost
balanced.
Regarding the statutory German efficiency principle for drug
prescription it is noteworthy that in the cohort study the
proportion of NNRTI-based cART increased rapidly at the end
of the 1990s (Figure 1), resulting in a preponderance since 2000 for
the first and second line regimen over the more expensive PI/r-
based cART. Interestingly, PI/r use was more common in the first
than in the second line regimen. A potential rationale for
preferring a PI/r-based induction therapy is the improved
resistance of the PI class in cases with a high viral load at the
start of treatment [17]. Accordingly, when analysing the changes
following the administration of first line therapy, we found fewer
changes from NNRTI to PI/r-based regimens than PI/r-induced
patients switching to a second line NNRTI regimen, soon after
their HIV viral loads were beyond the limit of detection. Assuming
that, hypothetically, up to 90% of PI/rs could be substituted by
less expensive NNRTIs, this would result in cumulative savings of
up to 20% of the daily treatment costs in the group of patients on
the first line treatment. The potential impact of such an approach
on the long-term outcome and cost efficacy needs further
investigation. Additionally, a putatively more convenient antiret-
roviral regimen or a specific desire of the patient could result in the
prescription of more expensive regimens. All these reasons might
additionally explain the considerable heterogeneity in the
documented regimens within this study.
Nucleoside/nucleotide analogues were used as the backbone of
virtually all regimens during the whole observation period.
However, the proportion of nRTI-sparing regimens increased
with the availability of new drug classes from 2003 and remained
at more than 1% until 2008 (Figure 1). Within the nRTI class,
zidovudine and lamivudine were predominantly used in the
beginning of the observation period. Following the release of
tenofovir and emtricitabine in 2001 and 2003, respectively,
zidovudine-containing backbones decreased and tenofovir-based
backbones radically increased thereafter (Figure 3). The nRTIs are
Table 4. Regimen lines over time (observed patient quarters
in selected years).
1996 2000 2004 2008
Number of observed patient
quarters per year
5216 17306 23776 25570
% with 1st-line cART 39.3% 26.8% 25.7% 21.6%
Mean # of treatment line 2.5 3.9 4.7 5.0
Maximum # of treatment line 20 37 40 48
doi:10.1371/journal.pone.0023946.t004
Figure 4. Mean daily treatment costs of antiretrovirals by class and year after adjustment for the German consumer price index
(1996=100), annual increments of consumer price index in %: 1996: 1.4%, 1997: 1.9%; 1998: 1.0%; 1999: 0.6%; 2000: 1,4%; 2001:
1.9%; 2002: 1.5%; 2003: 1.0%; 2004: 1.7%; 2005: 1.5%; 2006: 1.6%; 2007: 2.3%; 2008: 2.6%.
doi:10.1371/journal.pone.0023946.g004
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cheap compared to most other antiretroviral drug classes.
Nevertheless, the cost impact of nRTIs is high (Figure 4) because
of the widespread use of double-nRTI-comprising regimens.
From 2003, newly licensed antiretroviral drug classes (FI,
INSTI, CCRI) became available. They were primarily licensed for
use in treatment-experienced patients exclusively. Cumulatively,
these new drugs accounted for less than 5% of ARV-regimens in
2008, but with an increasing tendency (Figure 2). Virtually all
nRTI-sparing regimens consisted of one ore more than one PI/r
and more recently they increasingly consisted of agents from the
new drug classes. Using the opportunity provided by the
increasing number of options, more regimens avoided the use of
nRTI drugs when the new drug classes became available. Prices
for drugs from the new antiretroviral drug classes and boosted PI
are relatively high compared to nRTIs or NNRTIs; therefore, the
use of nRTI-sparing treatment regimens remains a relatively
expensive alternative.
Cost impact of cART
Including the effects of the statutory 16% price cut for
pharmaceuticals in Germany in 2004 and adjusting for the
ascertained annual German consumer price indices (German
Federal Statistical Office 2010, www.destatis.de; 1996= 100%),
the real increase in daily drug prices for the prescribed cART
regimens in the cohort was 13.5% within the studied 10-year
period (Figure 4). This increase is comparably moderate when
considering that the many recently licensed antiretroviral drugs
are significantly more expensive than those licensed ten or fifteen
years ago. Substantial differences in drug prices exist between
different antiretroviral classes but the increase over time within
Figure 5. Direct costs of antiretrovirals per line of regimen (pharmacy prices including taxes in Euros. Fine-printed numbers represent
sample sizes. p,0.0001 for differences between regimen line groups).
doi:10.1371/journal.pone.0023946.g005
Figure 6. Means of daily taken pills (bit) and average costs of each single antiretroviral pill by year.
doi:10.1371/journal.pone.0023946.g006
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distinct antiretroviral classes was moderate, indicating that market
prices of the subsequently licensed antiretrovirals seem to be
orientated towards their competitors within rather than beyond
the limits of their classes.
Mapping of treatment costs for HIV in the German health
care system
Since 2009, all public health insurers in Germany have to
transfer the received insurance contributions to a governmental
stock. Out of this stock, they prospectively retrieve a capitation of
approximately J2000 and particular lump sums within a risk
structure compensation scheme (Morbi-RSA). In 2010, the
insurers retrieved a Morbi-RSA of J18,455.18 per year and
capita for each HIV-infected patient receiving antiretroviral
therapy. This study found that the HIV-specific Morbi-RSA
nearly exactly covered the calculated mean costs of ARV regimens
(J18,268/year) in 2008. However, drug prices have risen since
2008 and a lump sum, which exclusively covers the direct costs of
cART, does not cover the direct costs of concomitant drug
therapy, hospitalization or regular check-ups and therefore might
indicate an underfunding for people living with HIV and AIDS
(PLWHA) by the Morbi-RSA. This could cause discrimination,
especially of PLWHA in the advanced stages of HIV within the
German health care system in the future, especially if the Morbi-
RSA is not adapted adequately. Analysis of data from German
health insurance companies potentially underestimates the cost
impact of cART in PLWHA. Insurance databases include a
significant proportion of single prescriptions of antiretroviral
drugs, presumably for post-exposure prophylaxis [18]. This
underlines the impact of treatment cohort data for the calculation
of lump sums such as the Morbi-RSA in the future.
Justification of the use of generic antiretrovirals instead
of branded drugs
Patent protection allows the license holder exclusive marketing
and price negotiations for a defined time period after the approval
of a new drug and this is regulated by national and international
laws. Product licences for the treatment of HIV/AIDS, cancer and
neurodegenerative diseases will have a longer period of exclusivity
compared to other drugs due to different approval systems in the
EU (10 years vs. 8 years; www.emea.com). After that third party
suppliers are allowed to claim a license for a chemically identical
drug.. All generic drugs approved by the EMEA and FDA have
the same high quality of ingredients, strength, purity and stability
as brand-name drugs. Generic drug manufacturers must show that
a generic drug is bioequivalent to the brand-name drug, which
means the generic version delivers the same amount of active
ingredients into a patient’s bloodstream in the same amount of
time as the brand-name drug. They must have the same dosage
form (for example tablets, liquids) and must be administered in the
same way. Generic drug labelling must be essentially the same and
generic drug manufacturers must fully document the generic
drug’s chemistry, manufacturing steps and quality control
measures. Moreover, the generic manufacturing, packaging, and
Table 5. Total costs of antiretroviral therapy by selected antiretroviral components potentially replaceable by generics in future
(cumulative sum in J per period, and % of costs of the entire regimen).
1996–2008 2005 2006 2007 2008
Observed patient quarters (n) 249,340 25,406 25,210 25,823 25,570
AZT 96,711,539 (11.9%) 9,763,763 (11.7%) 8,614,916 (9.5%) 8,166,949 (8.0%) 5,698236 (6.2%)
3TC & FTC 143,208,236 (17.6%) 14,510,090 (17.4%) 16,068,364 (17.7%) 17,694,612 (17.3%) 15,732,138 (17.1%)
NVP & EFV 120,645,732 (14.8) 12,504,141 (15.0%) 11,707,680 (12.9%) 13,850,164 (13.6%) 10,643,741 (11.6%)
AZT, 3TC, FTC, NVP, and EFV 360,565,506 (44.4%) 36,777,993 (44.1%) 36,390,960 (40.2%) 39,711,724 (38.9%) 32,074,114 (34.9%)
All other ARVs 452,311,850 (55.6%) 46,566,447 (55.9%) 54,173,304 (59.8%) 62,455,933 (61.1%) 59,740,7217 (65.1%)
Entire regimens 812,877,356 (100%) 83,344,440 (100%) 90,564,264 (100%) 102,167,657 (100%) 91,814,831 (100%)
doi:10.1371/journal.pone.0023946.t005
Table 6. Daily costs of antiretroviral therapy components (Euros/per day).
1996–2008 2005 2006 2007 2008
Mean daily costs in Euros of the entire regimen
(+/2 standard deviation)
J 42.08
(+/213.68)
J 41.83
(+/211.74)
J 43.89
(+/213.51)
J 48.13
(+/214.89)
J 50.05
(+/216.47)
Potential for savings by generics in
% of entire direct costs, assuming:
30% price reduction 14.5% 14.3% 13.4% 12.8% 11.8%
60% price reduction 29.0% 28.5% 26.8% 25.7% 23.6%
90% price reduction 43.5% 42.8% 40.2% 38.5% 35.4%
Saving in % of entire direct costs,
assuming:
Progressive scenario:
90% reduction, 90% substitution
39.1% 38.5% 36.2% 34.7% 31.8%
Conservative scenario: 20%
reduction, 20% substitution
1.9% 1.9% 1.8% 1.7% 1.6%
Sensitivity analysis modelling of potential price reduction in % for different scenarios of price reduction in the case of availability as a generic drug and for different
quotas of patients treated with generic drugs (standard deviation for costs; mean cost saving of the entire regimen in %).
doi:10.1371/journal.pone.0023946.t006
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testing sites must pass the same quality standards as those of brand
name drugs (FDA Requirements for Generic drugs; http://www.
fda.gov/Drugs/ResourcesForYou/Consumers/ucm143545.
htm#require). As for all medicines, the safety of generic medicines
continues to be monitored after authorisation. Each company is
required to set up systems to monitor the safety of all medicines
that it markets. Regulatory authorities may also perform an
inspection of these monitoring systems. If specific safety precau-
tions have to be considered when taking the reference medicine,
the same precautions will generally also be required for the generic
medicine (questions and answers on generic medicines; EMEA 17
March 2011 EMA/393905/2006 Rev. 1).
However, considerable differences in the efficacy and tolerabil-
ity of generic drugs had been found [19,20] despite of
pharmacokinetic bioequivalence. Based on this, additional studies
should be demanded by regulatory authorities assuring the
pharmacodynamic bioequivalence of generic drugs by additional
clinical studies.
Therefore an exchange of branded drugs by generics without a
proven bioequivalence might be problematic at least in individual
cases. In the context of cART the adherence to treatment is crucial
for the long term success [21] Hence it might be harmful to change
fixed antiretroviral combination drug therapies to the (generic)
single components. Considerable concerns may arise in case of
exchanging similar but not identical drugs motivated only by the
potential of cost savings, as discussed for the antiretroviral drugs
lamivudine and emtricitabine, which had been included as one
additional change option in the analysis. However, even the
exchange of different but similar effective drugs within the same
indication had been demanded as a consequence of the economic
efficiency principle within the German Social Insurance Code,
although the harm and benefit profiles of target and alternative
drugs within such an approach remains controversial [22].
Therefore from a scientific point of view determining the impact
on long-term outcome of drug exchange is a rational approach
before its widespread use for economic reasons should be claimed.
To avoid unwanted health system and health effects policy makers
should assure or fund adequate studies in this field.
Cost impact scenarios for the potential introduction of
generic antiretrovirals
Until recently, all antiretroviral drugs in Germany were
protected by patents and were exclusively available as branded
labels. However, patent protection for zidovudine (AZT) and
lamivudine (3TC) has recently expired and it will expire for
nevirapine (NVP) and efavirenz (EFV) in the near future. In 2010,
3TC became available as a generic drug within the European
Union (EU) exclusively. In Spain, price reductions of up to 55%
can be found compared to branded 3TC (PMFarma 2010; www.
pmfarma.es).
Generics are able to induce substantial price reductions for
pharmaceuticals. The impact of antiretroviral generics on the
direct costs of cART depends on the willingness to prescribe them
broadly [8,23].
Assuming that generic drugs will become widely available and
will have an equivalent bioavailability and tolerability as branded
drugs, a high penetration of the market segment will possibly be
achieved. In addition with the availability of generic lamivudine,
an economically based substitution of emtricitabine by generic
lamivudine might also occur. The cytidine analogues emtricitabine
and lamivudine have a similar resistance profile [24] and both are
generally well tolerated [25]. However, different in vitro and in
vivo activities and pharmacokinetic properties indicate that these
two drugs might not be mutually exchangeable. [26]. Of all drug
costs in the years 2005 to 2008, 35% to 44% came from drugs
suitable for exchanging with generics (Table 6). With an exchange
rate of 20% to 90% and price cuts from 20% to 90%, potential
cost savings of 1.6% to 31.8% would result within these presumed
ranges. This potentially equals mean annual savings of J292.29
up to J6,466.96 per patient. It was estimated that, in Germany,
approximately 35,000 people received cART in 2008 [27]. Cost
savings for the German health care system based on the
introduction of generic antiretroviral drugs will be high (10
million Euros to 200 million Euros per year). Moreover, indirect
cost savings might also result in the reduction of the average price
of the brand name drugs that are still purchased [23].
Consequently, the introduction of generic antiretroviral drugs
would potentially change the recent market situation substantially.
However, some disadvantages may arise by the introduction of
generic drugs. There might be an increase in the pill burden
caused by the unbundling of branded co-formulations. This might
influence the adherence of patients. Although there is evidence
that a high pill burden, a high frequency of dosing or both
inversely correlate with patient adherence, there is little evidence
for a certain threshold in the number of items swallowed daily or
an advantage of the administration frequency as long as it is below
three times per day. Therefore, it remains more crucial to find an
individually tolerable drug combination than to minimize the pill
burden [28]. But adherence is highly correlated with the long-term
success of antiretroviral therapy. Therefore, efforts are needed to
ensure that a change between branded and generic antiretroviral
drugs will not adversely affect individual adherence. As a matter of
course in cases with a known intolerability to elements of an
alternative drug, an exchange is a priori contraindicated.
Assuming that the number of PLWHA in Germany will
increase and as recent guidelines recommend treatment at earlier
stages of asymptomatic HIV infection and at CD4+ T cell counts
of less than 500/ml, many more patients will receive cART in the
future. The German nationwide potential for annual cost savings
by choosing economically priced antiretroviral regimens could
increase up to more than 500 million euros per annum within the
next few years. But this goal will be hard to achieve. Even if
patients and physicians could be incentivized to consider
economically alternative regimens, they will often choose a more
expensive alternative [29]. Beneficiaries of less expensive treat-
ment regimens would be the foremost payers. Hence, stakeholders
have to consider how to redirect at least part of the savings to
finance incremental costs for medical progress in the future.
Choosing economical alternatives in antiretroviral treatment
does not necessarily mean that the pharmaceutical industry will
lose earnings and market share in the future.
The development of new innovative antiretroviral co-formula-
tions will be simplified by the availability of generic antiretroviral
drugs.. This could result in advantageous treatment options for the
patients. By this way, license holders of still branded antiretroviral
drugs would get the opportunity to improve their portfolio and to
increase their sales volume and profits.
Cost calculations from a representative, disease-specific clinical
cohort, like ClinSurv, could have an impact on future cost
savings. This approach would allow future definition of the cost
impacts of particular subgroup treatments, for example patients
in progressed stages of treatment, more precisely for the health
care system and its stakeholders. In addition, it would allow the
cost impacts of evolutionary changes in treatment guidelines and
transitions within the German health care system to be evaluated
in a prospective manner [30]. Therefore, accompanying
ecological research using data of the ClinSurv cohort might
improve the allocation of economic resources in health services
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and define specific goals for sustainable reforms of the health care
system.
Potential applicability of the findings in the study to
other health care settings
The market for antretroviral drugs in the world is subdivided
into at least three parts: By international policies, funding, gradual
national prizing, and waiver of license fees by some patent holding
pharmaceutical companies in middle- and low-income countries
the drug prices vary considerably from those in the high-income
countries. As discussed above the data in this study are generated
from the German ClinSurv cohort using the nationwide official
German pharmacy prices, which are by several reasons in an
upper range even compared to other countries with a high per
capita gross national product. Therefore data and conclusions
from this study can not be generalised to the situation in low- and
middle-income countries. Due to several unique characteristics of
the German health care system and particular regulatory issues
any comparison with other contrastable rich countries should be
used cautiously.
Limitations of the study
N The study focuses exclusively on direct cost for antiretroviral
treatment. Other direct costs of treatment, indirect costs and
intangible costs remain disregarded.
N Updates of treatment guidelines may be of high impact on
treatment costs and may reduce the number of potentially cost-
saving alternative treatment choices. Such potential effects for
the future had not been calculated in the study.
N The used cohort data may reflect predominantly a real clinical
life scenario but do not allow to investigate strategic issues,
which would be addressed more accurately in a controlled
clinical trial. Basically, there is a need for such trials, especially
in the field of health economics. On the other hand policy
makers and stakeholders have to deal with existing regulatory
issues within the public health system. Beside the description of
the recent cost impact of cART the presented study intends to
describe a potential short-term economic impact on direct
costs, by using generic antiretrovirals in a variable extent
Remaining concerns regarding ethical issues to interchange
branded antiretroviral drugs with generic antiretroviral drugs
can neither be confuted nor confirmed by the study.
N Drug prices and regulatory issues are specifically taken from
the German health care system and a comparison or
generalisation of data and conclusions from this study to other
health care settings should be performed with caution.
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